Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2008

View Archived Issues

New agents for treating neurological disorders disclosed in recent patent literature

Naproxcinod meets all primary endpoints in final pivotal trial

New non-nucleoside HCV polymerase inhibitor from Idenix described

Schering-Plough presents overview of recent pipeline activity

Pharmacyclics completes and reports positive results from phase I clinical trial of PCI-27483

Dako collaborates with Genentech on diagnostic for targeted cancer therapy

Alzheimer's Drug Discovery Foundation helps fund Varinel's AD program

Wyeth and Progenics present positive outcome of phase III Relistor trial

Studies explore nitazoxanide mechanism, shorted lead-in treatment in HCV

Sosei outlicenses malaria treatment to Treague

EMEA approves Lux's Pediatric Investigation Plan for Luveniq in uveitis

No difference between CERE-120 and control in phase II clinical trial in PD

S-24795, an alpha7 nAChR partial agonist, may be useful in Alzheimer's disease

Chugai files application in Japan for additional indication for Avastin in NSCLC

Abraxis sings agreement with AstraZeneca to reacquire U.S. rights to Abraxane

Antiparkinsonian and neuroprotective effects of novel MAO-B inhibitor

New sodium channel blocker shows potential in models of epilepsy and psychiatric disorders

New compound prevents opioid-induced constipation with minimal effect on analgesia

Increased glycosuria seen with dapagliflozin in type 2 diabetes studies

SBR-759 lowers serum phosphorus in dialysis patients

Oxarol ointment and lotion receive approval in Japan for palmoplantar pustulosis

Recent Novartis patent reports new S1P1 receptor ligands intended for transplant rejection

New anticancer agents imparted in recent patents

FDA requests additional information regarding BLA for motavizumab

Lilly withdraws Cymbalta sNDA, plans to resubmit in 2009 with additional data

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...